Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
CGRP (Calcitonin Gene-Related Peptide)37 residuesACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: alpha-CGRP, CGRP-alpha, CGRP-I
One thousand times more potent than acetylcholine at relaxing blood vessels. CGRP (Calcitonin Gene-Related Peptide) is a 37-amino-acid neuropeptide that became the molecular foundation for the most successful migraine drug class developed in the past two decades. Four monoclonal antibodies and three small-molecule gepants now target this single peptide pathway. The peptide itself, however, remains a research-only compound. A plasma half-life of 6.9 minutes and potent hypotensive effects have kept exogenous CGRP confined to controlled IV infusion studies. Researchers use it to probe trigeminal neurovascular physiology, cardiovascular regulation, and wound healing biology.
Calcitonin Gene-Related Peptide, or CGRP (alpha isoform, encoded by the CALCA gene; CAS 83652-28-2), is a 37-amino-acid neuropeptide and the most potent endogenous vasodilator ever identified. On a molar basis it relaxes vascular smooth muscle roughly 1,000 times more effectively than acetylcholine. Four FDA-approved monoclonal antibodies and three gepant receptor blockers exist because of this single molecule. The path from peptide to drug target started with two findings. Goadsby and colleagues [1] measured raised CGRP in jugular venous blood during spontaneous migraine attacks. Then Lassen's group [2] showed that IV CGRP infusion at 1.5 mcg/min for 20 minutes triggered migraine-like headache in 66% of migraineurs. That provocation model became the foundation for developing erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), eptinezumab (Vyepti), ubrogepant (Ubrelvy), rimegepant (Nurtec), and atogepant (Qulipta), all approved between 2018 and 2022. Beyond migraine, CGRP shows cardioprotective properties in ischemia-reperfusion models and accelerates wound closure in diabetic mouse models (Lu YZ et al., Nature 2024)[3]. But the peptide itself has no approved therapeutic indication. That 6.9-minute plasma half-life requires continuous IV infusion, and the potent systemic vasodilation makes outpatient use impractical. CGRP remains a research tool, not a therapeutic product.
CGRP binds a heterodimeric receptor built from calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). A third protein, receptor component protein (RCP), locks in the G protein coupling. Once CGRP docks onto CLR/RAMP1, the primary cascade runs through Gs signaling. Adenylyl cyclase fires up, intracellular cyclic AMP (cAMP) rises, and protein kinase A (PKA) gets to work. In vascular smooth muscle, PKA phosphorylates KATP channels and myosin light chain phosphatase. Both actions relax the muscle wall and dilate the vessel. Some vascular beds add an endothelium-dependent layer; CGRP activates endothelial nitric oxide synthase (eNOS), releasing nitric oxide for additional vasodilation. The receptor also signals through beta-arrestin pathways after internalization into endosomes. Sustained cAMP production continues inside the cell even after plasma CGRP is gone. That endosomal signaling likely explains why vasodilatory effects persist 20 to 40 minutes beyond the peptide's 6.9-minute clearance. In trigeminal sensory neurons, CGRP released from peripheral terminals in the dura triggers a cascade: dural vasodilation, mast cell degranulation, plasma protein extravasation, and sensitization of second-order trigeminocervical neurons. This is the core pathophysiology of migraine. CGRP also sensitizes its own release from neighboring neurons, creating a positive feedback loop that sustains and amplifies the attack.
CGRP is the most potent endogenous vasodilator and the central molecular target in migraine pathophysiology. Exogenous CGRP infusion is validated as the gold-standard migraine provocation model. Cardioprotective and wound-healing effects are documented in preclinical models; no approved human therapeutic indication exists for the peptide itself.
Lassen LH et al. (2002, PMID 11952980): IV CGRP (1.5 mcg/min × 20 min) triggered migraine-like headache in 66% of migraineurs. Goadsby PJ et al. (1990, PMID 2473557): serum CGRP elevated in jugular blood during spontaneous migraine attacks. Lu YZ et al. (Nature 2024, PMID 38538784): engineered eCGRP construct accelerated wound closure ~2.5x in diabetic mouse models.
6.9-minute half-life requires continuous IV infusion; no human therapeutic trials for cardioprotection or wound healing have completed Phase II. 2024 wound healing data (PMID 38538784) used an ECM-anchored eCGRP construct, not native peptide. No full-length agonist CGRP with extended half-life has reached clinical trials as of April 2026.
No self-administration community exists for exogenous CGRP peptide. Discussion on r/migraine (~200K members) focuses exclusively on FDA-approved anti-CGRP monoclonal antibodies. Zero documented cases of consumer peptide self-injection confirmed across all major peptide communities as of April 2026.
No community self-administration exists. All protocols and evidence derive exclusively from controlled clinical research settings with IV infusion and hemodynamic monitoring. Community discussion of the CGRP pathway concerns FDA-approved anti-CGRP antibody drugs, not the peptide itself.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | Single dose |
| Moderate | 30mcg | Single dose |
| Aggressive | 60mcg | Single dose |
CGRP is not a self-administration peptide. This needs to be stated plainly because the peptide shows up in search results alongside injectable peptides that people do use at home. The 6.9-minute half-life means subcutaneous injection produces a brief, unpredictable hemodynamic event with no sustained benefit. Every published human study used IV infusion with continuous blood pressure monitoring. Reconstitution math for research settings: a 0.5 mg (500 mcg) vial reconstituted with 2 mL bacteriostatic water yields 250 mcg/mL. For the standard migraine provocation dose of 1.5 mcg/min over 20 minutes (30 mcg total), you'd need 0.12 mL of that solution diluted into an IV infusion bag. A 1 mg vial with 2 mL gives 500 mcg/mL. The detail most people miss: CGRP adsorbs to glass and plastic surfaces at low concentrations. Below 10 mcg/mL, add 0.1% BSA (bovine serum albumin) as a carrier protein and use siliconized or protein low-bind containers. Skip this step and your actual delivered dose could be noticeably lower than intended.
No established human cycling protocol exists for exogenous CGRP administration. The extremely short half-life (~6.9 minutes) necessitates continuous IV infusion for sustained effects, which is impractical outside controlled research settings. Human infusion studies have typically used single-dose protocols (1.5-3 mcg/min for 20 minutes). Repeated dosing may lead to tachyphylaxis of vasodilatory responses. Cycling parameters shown are theoretical placeholders. Any investigational use requires continuous hemodynamic monitoring.
No established cycling protocol exists for exogenous CGRP. Human research has been limited exclusively to single-dose IV infusion sessions due to extreme hemodynamic risk. Receptor desensitization via rapid CLR/RAMP1 internalization occurs within minutes of exposure. Tachyphylaxis of the vasodilatory response is documented with repeat infusions in the same session. The cyclingProtocol values in the source file (onWeeks: 1, offWeeks: 4) are explicitly acknowledged placeholders with no scientific basis: any investigational repeat use requires full hemodynamic recovery between sessions.
Or use the universal Peptide Calculator for any peptide.
Expected: Immediate vasodilation, flushing (~99%), BP reduction 10–30 mmHg systolic, reflex tachycardia. Delayed migraine-like headache in 60–75% of migraine-susceptible subjects within 1–5 hours post-infusion.
Monitor: Continuous BP, HR, and SpO2 during infusion. Record headache onset/severity hourly for 12 hours. IV vasopressor (phenylephrine 50–100 mcg or norepinephrine) on standby.
Confirm setting: continuous blood pressure monitoring (intra-arterial line preferred), ECG telemetry, peripheral IV access, and vasopressor (phenylephrine 50 to 100 mcg IV) on standby. Subject supine.
Reconstitute: add 2 mL bacteriostatic water to lyophilized vial. Gently swirl until dissolved. Do not vortex. A 0.5 mg vial yields 250 mcg/mL; a 1 mg vial yields 500 mcg/mL.
Prepare infusion: for the standard 1.5 mcg/min dose, calculate total volume needed for 20 minutes (30 mcg total = 0.12 mL of 250 mcg/mL solution). Dilute into normal saline for infusion pump delivery. Use protein low-bind tubing; add 0.1% BSA to diluent if concentration falls below 10 mcg/mL.
Record baseline blood pressure and heart rate immediately before starting.
Monitor continuously: BP and HR every 1 to 2 minutes during infusion. Alert thresholds are systolic drop greater than 20 mmHg from baseline, absolute systolic below 90 mmHg, or sustained HR above 130 bpm.
Stop infusion immediately if: systolic BP drops more than 30 mmHg, HR exceeds 130 sustained, SpO2 falls below 92%, or subject requests discontinuation.
Post-infusion monitoring: keep subject supine for 60 minutes minimum. Record headache severity (VAS or NRS) at 30 min, 1h, 2h, 4h, and 12h. Do not allow standing until BP returns within 10 mmHg of baseline.
Storage: reconstituted solution is stable for up to 48 hours at 2 to 8 degrees C. Do not refreeze. Prepare fresh on study day when possible.
0.5–3 mcg/min × 20 min = 10–60 mcg total administered. Reference route (100% bioavailability).
Infusion pump required. Peripheral IV line adequate; central line preferred for high-dose protocols. Continuous hemodynamic monitoring mandatory.
Investigational dose range 10–60 mcg SC (based on IV total-dose equivalence). No established SC protocol in modern literature.
Local erythema and warmth at injection site expected (local vasodilatory effect). Hemodynamic monitoring still required. Not used in contemporary migraine or cardioprotection research protocols.
Additive hypotension with CGRP-mediated vasodilation. Risk of severe, potentially refractory hemodynamic compromise.
Do not combineSynergistic NO-mediated and cAMP-mediated vasodilation. Severe hypotension risk. Contraindicated combination.
Do not combineDirect pharmacological antagonism: mAbs block the CLR/RAMP1 receptor or CGRP ligand, negating exogenous CGRP effects and creating unpredictable pharmacology.
Do not combineSmall-molecule CGRP receptor antagonists. Block CLR/RAMP1 activation by exogenous CGRP. Active elimination half-lives of 5–11h may persist at time of any CGRP infusion.
Do not combinePricing updated 2026-04-09
Profound, dose-dependent hypotension is the most serious risk with exogenous CGRP. IV infusion studies report systolic blood pressure drops of 10 to 30 mmHg. At high doses, blood pressure can fall far enough to require IV fluid bolus or vasopressor intervention with phenylephrine (50 to 100 mcg IV). This is not a mild inconvenience; it's a medical event that demands continuous hemodynamic monitoring and vasopressor standby before any infusion begins. Facial flushing occurs in virtually all subjects at pharmacological doses. Published figures put it at approximately 99%. The flushing reflects CGRP's vasodilatory mechanism acting on cutaneous vasculature. Warmth, cutaneous erythema, and a sensation of heat throughout the body accompany the flushing. Reflex tachycardia follows the blood pressure drop. Heart rate increases as the cardiovascular system compensates for reduced vascular resistance. A 2026 FAERS analysis [5] flagged palpitation signals across the entire CGRP pathway drug class, raising the monitoring bar even further. The migraine provocation effect is perhaps the most distinctive side effect of any peptide. In migraine-susceptible individuals, CGRP infusion triggers delayed migraine-like headache in 60 to 75% of subjects, typically peaking 1 to 5 hours after infusion ends (Lassen et al.)[2]. This reflects sustained trigeminal sensitization rather than ongoing peripheral CGRP activity, since the peptide clears in under 7 minutes. Nausea, dizziness, and lightheadedness related to blood pressure reduction are common during and immediately after infusion. Long-term effects of exogenous CGRP are unknown. All published human data comes from single infusions or very short courses. Theoretical concerns include exacerbation of inflammatory conditions (CGRP drives neurogenic inflammation) and interference with bone metabolism. Contraindications are strict. Hypotension or hemodynamic instability, active migraine, severe cardiovascular disease, concurrent potent antihypertensives, pregnancy, and breastfeeding all disqualify a subject. Administration outside a setting with continuous hemodynamic monitoring, IV access, and vasopressor availability is not appropriate for any reason.
Verify CGRP (Calcitonin Gene-Related Peptide) dosing and safety with a second opinion
Research chemical with no consumer gray-market supply chain. Sourced exclusively from specialty biochemical suppliers (Bachem, Tocris/Bio-Techne, AnaSpec, Sigma-Aldrich). Potent hemodynamic effects mean any degraded, misidentified, or adsorption-affected preparation carries compounded danger beyond typical peptide quality risk.
| Test | When | Target |
|---|---|---|
| Continuous blood pressure (intra-arterial line preferred; cuff minimum) | Throughout infusion and for 60 min post-infusion | Alert threshold: systolic >20 mmHg drop from baseline or absolute systolic <90 mmHg |
| Heart rate / ECG telemetry | Throughout infusion and 60 min post-infusion | Alert threshold: HR >130 bpm sustained or symptomatic palpitations |
| Headache severity (VAS 0–10 or NRS) | Baseline, end of infusion, then at 30 min, 1h, 2h, 4h, 12h post-infusion | — |
| Plasma CGRP concentration (research settings) | Pre-infusion, during infusion peak, 7 min, 20 min, and 40 min post-infusion | — |
| Skin temperature / forearm blood flow (laser Doppler or plethysmography) | During infusion in vascular physiology studies | — |
CGRP causes dose-dependent hypotension (10–30 mmHg systolic). Real-time monitoring required for both safety and dose-response characterization.
Reflex tachycardia is expected; FAERS 2026 (PMID 41706150) documents class-wide palpitation signals across all CGRP pathway drugs. ECG characterizes rhythm and excludes arrhythmia.
CGRP provokes delayed migraine-like headache in 60–75% of susceptible subjects. Primary efficacy/safety endpoint in migraine research protocols.
Characterizes PK (t½ ~6.9 min) and confirms dose delivery. Measured by RIA or LC-MS/MS. Required for PK studies; optional for provocation studies.
Objective measure of peripheral vasodilation response for dose-response characterization.
Rapid onset of vasodilatory effects following IV infusion. Facial flushing and warmth detectable within 1-2 minutes. Measurable reduction in systemic vascular resistance and blood pressure. Heart rate increases reflexively. Peak plasma CGRP concentrations achieved during infusion.
Sustained vasodilation during infusion period. Blood pressure nadir typically reached during or shortly after the infusion. Skin temperature elevation in extremities. In migraine-susceptible individuals, premonitory migraine symptoms may begin (photophobia, nausea). cAMP-mediated smooth muscle relaxation at maximal effect.
After infusion cessation, plasma CGRP levels decline rapidly (t1/2 ~6.9 minutes). Hemodynamic parameters begin normalizing within 10-15 minutes post-infusion. Flushing resolves. However, endosomal CLR/RAMP1 signaling may sustain intracellular cAMP elevation beyond peptide clearance.
Plasma CGRP fully cleared. In migraine-susceptible subjects, delayed migraine-like headache develops in 60-75% of individuals, typically peaking 1-5 hours post-infusion. This delayed headache likely reflects sustained trigeminal sensitization and central processing rather than ongoing peripheral CGRP signaling.
Complete resolution of direct hemodynamic effects. Migraine-like headache, if triggered, may persist for hours and responds to standard migraine treatments including triptans. Cardioprotective effects observed in preclinical ischemia models peak during the early reperfusion period following CGRP pre-treatment.
Minutes 0 to 5: Vasodilation begins fast. Facial flushing and warmth show up within 1 to 2 minutes of starting the IV infusion. Systemic vascular resistance drops measurably. Heart rate climbs as a reflex response. Plasma CGRP hits peak concentration while the infusion runs. Minutes 5 to 20: Blood pressure reaches its lowest point around 10 to 15 minutes into the infusion. Skin temperature rises in the extremities. cAMP-mediated smooth muscle relaxation is at full effect. Migraine-susceptible individuals may start noticing premonitory symptoms like photophobia or nausea during this window. Minutes 20 to 40: After the infusion stops, plasma CGRP drops rapidly with a half-life of about 6.9 minutes. Hemodynamic numbers start returning to baseline within 10 to 15 minutes. Flushing fades. But endosomal CLR/RAMP1 signaling can keep intracellular cAMP raised longer than the peptide stays in circulation. 1 to 5 hours post-infusion: Plasma CGRP is completely cleared by this point. The delayed headache window opens. In 60 to 75% of migraine-susceptible subjects, a migraine-like headache develops and typically peaks during this period. The headache reflects central trigeminal sensitization, not residual peripheral CGRP activity. 6 to 24 hours post-infusion: All direct hemodynamic effects have resolved. If a migraine-like headache was triggered, it responds to standard migraine treatments including triptans (sumatriptan 50 to 100 mg oral or 6 mg subcutaneous). No documented next-day effects from a single infusion session.
Facial flushing and warmth detectable within 1–2 minutes. Measurable reduction in systemic vascular resistance. Reflex tachycardia begins. Peak plasma CGRP concentrations during infusion.
N/A: research setting only
Sustained vasodilation. BP nadir typically at 10–15 min into infusion. Skin temperature elevation in extremities. Maximal cAMP-mediated smooth muscle relaxation. Premonitory migraine symptoms may begin in susceptible individuals.
N/A
Post-infusion plasma CGRP declines rapidly (t½ ~6.9 min). Hemodynamics begin normalizing within 10–15 min of infusion end. Flushing resolves. Endosomal CLR/RAMP1 signaling may sustain intracellular cAMP elevation beyond peptide clearance.
N/A
Plasma CGRP fully cleared. Delayed migraine-like headache develops in 60–75% of migraine-susceptible subjects. Reflects sustained trigeminal sensitization and central processing, not ongoing peripheral CGRP signaling.
N/A
Complete resolution of hemodynamic effects. Provoked headache (if present) responds to standard migraine treatment. No known next-day effects from a single infusion.
N/A
Source: Plasma t1/2 of alpha-CGRP is approximately 6.9 minutes in humans following IV infusion. Rapid clearance via neutral endopeptidase (NEP) degradation and hepatic/renal elimination (Kraenzlin et al., 1985, PMID 3489420; Brain & Grant, 2004, PMID 15207852)
Loading the interactive decay curve.
CGRP peptide has no FDA-approved therapeutic indication. Its regulatory status is research-only. The peptide is available exclusively from specialty biochemical suppliers (Bachem, Tocris/Bio-Techne, AnaSpec, Sigma-Aldrich) for laboratory and clinical research use. Seven drugs targeting the CGRP pathway are FDA-approved for migraine (erenumab, fremanezumab, galcanezumab, eptinezumab, ubrogepant, rimegepant, atogepant), but these block CGRP signaling rather than providing it. The peptide itself is a different product entirely. No consumer gray-market supply chain exists for CGRP. WADA status is not applicable as there is no performance-improving use case. Any human administration requires IRB approval, informed consent, and a clinical research protocol with appropriate hemodynamic safety measures. This content is for educational and research reference purposes only. It does not constitute medical advice, and nothing here should be interpreted as a recommendation to administer CGRP to humans outside of approved research protocols.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
